39. Assmann, G. HDL cholesterol as a predictor of coronary heart disease risk. The
PROCAM experience and pathophysiological implications for reverse cholesterol
transport / G. Assmann, H. Schulte, A. Von Eckardstein, et al. // Atherosclerosis.
- 1996.-V o l . 124. - S11-S20.
40. Austin, M.A. Low density lipoprotein subclass patterns and risk of myocardial
infarction / M.A. Austin // JAMA. - 1988. - Vol. 260. - P. 1917-1921.
41. Barr, D.P. Protein - lipid relationship in human plasma / D.P. Barr, E.M. Russ,
H.A. Elder // Am J Med. - 1 9 5 1 , -Vol. 11. - P.480-493.
42. Baskes L.M. et al. Fibrates: what have we learned in the past 40 years?
Pharmacotherapy. - 2007. - Vol. 27(3). - P.412-424.
43. Beteridge, D.J. The interplay of cardiovascular risk factors in the metabolic
syndrome and type 2 diabetes / D.J. Beteridge // Eur Heart J. - 2004. - Vol. 6
(suppl. G). - G3-G7.
44. Bissonnette, R. Fenofibrate raises plasma homocysteine levels in the fasted and
fed states. / R. Bissonnette, E. Treacy, R. Rozen, et al. // Atherosclerosis. -2001 .
-V o l. 155. - P.455-462.
45. Bjorntop, P. «Portal» adipose tissue as a generator of risk factors for
cardiovascular disease and diabetes / P. Bjorntop // Aterosclerosis. - 1990. - Vol.
10. - P.493-496.
46. Blankenhorn, D.H. The Monitored Atherosclerosis Regression Study (MARS):
Coronary angiographic changes with lovastatin therapy. / D.H Blankenhorn //
Ann Intern Med. - 1993. — Vol. 119. — P.969—976.
47. Bobek, P. Dietary mushroom (Pleorotus ostreatus) ameliorates atherogenic lipid
in hypercholesterolaemic rats // P.Bobek, O. Ozdin, M. Micus // Clin. Exp.
Pharmacol. - 2003. - Vol. 30(7). - P.470-475.
48. Borkan, G. Body weight and coronary disease risk: patterns of risk factor change
associated with long-term weight change. The normative ageing study / G.
Borkan., D. Sparrow, C. Wisnrewski, et al. // Am J Epidem. - 1986. - Vol. 124. -
P.410-419.
88
